Navigation Links
EasiLisa AP-22 Micro-Plate Processor

ProductsEasiLisa AP-22 Micro-Plate Processor
Company NUBENCO ENTERPRISES, INC.
Item EasiLisa AP-22 Micro-Plate Processor
Features 
  • Ap-22 can master all together in the same run 8 different methods with two different dilution bufferrs and two different washing solutions.
  • Sample rack for 40 or 60 primary tubes.
  • Volume dispensing: From 10 L to 1 ml by step of 1 L, with precision better than 0.2%
  • Needle: Able to detect the liquid surface
  • Reading system: 8 separated photometric channels to read a line of 8 wells at a time in monochromatic or bichromatic mode
  • Standard filters: 2 filters (450 and 630 nm) on board, 2 others (405 and 492) on request.
  • Different wavelengths as required from 400 nm to 700 nm
  • Accuracy: 2 % from 0.000 to 2.000 OD Abs, reading range from 0.000 to 3.000 OD
Description AP-22 Micro Plate Processor is a precise, reliable and technologically advanced Automated Microplate Analyzer. It has been designed for OEM production. Its reagent assigned area can be customised according to the method bottles size.

AP-22 Micro Plate Processor is able to process automatically the whole ELISA and EIA analytical protocols.

Info NUBENCO ENTERPRISES, INC.
Customer Service: 1-800-633-1322
Web site: http://www.nubenco.com/nubencowelcome.htm

Related medicine products :

1. STP 120 Spin Tissue Processor
2. Vysis VP2000 Processor
3. Shandon Excelsior Tissue Processor
4. Shandon Citadel Tissue Processor
5. Shandon Pathcentre Tissue Processor
6. MonoPrep® LBP Processor
7. COBE 2991 Cell Processor
8. MAP D-Type - Microplate Assay Processor
9. Shandon Excelsior ES™ Tissue Processor
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so
Ethicon Endo-Surgery provides disposable handheld instruments that provide reliable, precise performance every time. Our handheld instruments come in 5mm and 10mm sizes.
...aspiration holes and additional electrode tip insu...recise dissection with decreased risk of collatera... design options allow the choice between retractab...designs. Optimize specific surgical demands safely...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so
Medicine Products:
(Date:12/3/2008)... Dec. 3 Ten students pu...sey will receive $5,000 and $2,000 scholarships fr...at the Fifth Annual Hispanic Health Professional S... New York Marriott Marquis Hotel. , , The ... Foundation, who donated $15,000 for $5,000 awards...
(Date:12/3/2008)...E, R.I., Dec. 3 Blue Cross & B...England (CNE) today announced that they have,reac...CNE will remain in the,BCBSRI network until 2013....,Women & Infants, and Butler) and the VNA of...esident and CEO James E. Purcell, "These are,chal...
(Date:12/3/2008)...Dec. 3 A patient who was surgicall... product, for an off-label use promoted,by Medtro...ling, according to,James A. Dunlap Jr. & Asso...it,in California along with another national law ...things, that Medtronic improperly,promoted its In...
(Date:12/3/2008)...dy suggests the procedure impairs healthy immune r... News) -- Children born by Caesarean section are a...earchers, who conducted long-term monitoring of th... By the time they were 8 years old, 362 (12.4 perc...a for which they,d been prescribed inhaled steroid...
Breaking Medicine News(10 mins):Health News:NHHF Scholarship Program Targets Growing Demand for Diversity Among Health Care Professionals 2Health News:Medtronic, Inc. and Medtronic Sofamor Danek, USA, Inc. Sued for Product Liability and Promoting the Off-Label Use of Infuse(R) Bone Graft Product, According to Page Perry, LLC 2Health News:C-Section Might Boost Baby's Asthma Risk 2
...s than the standard weight seem to be at significa...ndrome or IBS, suggests research published// ahead...rs base their findings on 3334 twin pairs, 1250 of...eted a comprehensive questionnaire about their hea...
...e University of Virginia (UVa) and Reckitt-Benckis... is all very easy thanks // to the amount of viral... study was presented at the annual Interscience Co...hemotherapy (ICAAC). During daily activities, adul...
...student of the premier All India Institute of Medi...even as authorities // said measures were being ta...ampus. Kamal Raj Kiran was admitted in a special w...ive for dengue Thursday. His condition deteriorate...
...that prices of 200 brand name drugs which are take...during the 12 month period ending // mid June 2006...s conducted by AARP and reported in their Rx Watch... also reported that the prices of 75 commonly used...
Other Medicine News:Health News:Restricted Fetal Growth Increases Risk of Irritable Bowel Syndrome 2Health News:Common Cold All Too Easy To Catch 2Health News:Common Cold All Too Easy To Catch 3Health News:Common Cold All Too Easy To Catch 4Health News:AIIMS Student Dies of Dengue Fever 2Health News:Brand Name Drug Prices Zoom 2
(Date:12/3/2008)...swire-FirstCall/ -- Bionovo, Inc.,(Nasdaq: BNVI...ompany,s,manufacturing and control process descri...onovo can move forward with the development of Men...ashes. , "We have concluded three CMC discu...e Agency,s recommendations for further development...
(Date:12/2/2008)... -- IBT Laboratories, a leading clinical-diagnost...g in immunology and allergy assays, announced that...nse of patients whose immune systems may be compro...chemotherapy drugs, or because they are taking imm...ansplant. The company launched the two new assays,...
(Date:12/1/2008)... A study has found that...que for imaging the breast, is not affected by eit...wo factors that limit the effectiveness of standar... will be presented today at the annual meeting of ... , , "The ability of PEM to detect cancer d...
(Date:12/1/2008)...reated With ENB-0040 at Children,s Hospital, Healt... Dec. 1 Enobia Pharma, an emerging...vel therapeutics for serious bone disorders, today...inical program for hypophosphatasia was dosed. Eno...RT) with ENB-0040 for the treatment of this rare a...
Breaking Medicine Technology:Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings 2Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings 3Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings 4IBT Laboratories Expands its Menu of Tests for Immune Deficiency 2New Mammography Technology Effective in Detecting Breast Cancer 2New Mammography Technology Effective in Detecting Breast Cancer 3New Mammography Technology Effective in Detecting Breast Cancer 4Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 2Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 4Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 5Omron Healthcare Introduces New Device Drivers Built on Microsoft HealthVault 21289 1Omron Healthcare Introduces New Device Drivers Built on Microsoft HealthVault 21289 2Omron Healthcare Introduces New Device Drivers Built on Microsoft HealthVault 21289 3ChanTest Launches Redesigned Web Site 5877 1ChanTest Launches Redesigned Web Site 5877 2Raptor Pharmaceuticals Corp Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease 5875 1Raptor Pharmaceuticals Corp Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease 5875 2Raptor Pharmaceuticals Corp Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease 5875 3Raptor Pharmaceuticals Corp Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease 5875 4Raptor Pharmaceuticals Corp Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease 5875 5LMXonline Offers Spanish Language Safety and Health Training Library 5873 1LMXonline Offers Spanish Language Safety and Health Training Library 5873 2
...unces Positive Top-Line Phase III Results for,Kepp...izures in,Paediatric Patients from One Month to Le...ril 20, 2007 - UCB today announced,positive top-li...zed, multi-centre, placebo-controlled study evalua...(levetiracetam) (20-50,mg/kg/day) as adjunctive th...
...dy Demonstrated the Clinical Potential of Peregrin...ere as Effective as,Avastin(R) in Animal Cancer Mo...irstCall/ --,Peregrine Pharmaceuticals, Inc. , a c... targeted monoclonal antibodies,for the treatment ...eported that data from multiple studies presented ...
Other Medicine Technology:UCB Announces Positive Top-Line Phase III Results for Keppra as,Adjunctive Therapy for Partial Onset Seizures in Paediatric,Patients from One Month to Less than Four Years of Age 2UCB Announces Positive Top-Line Phase III Results for Keppra as,Adjunctive Therapy for Partial Onset Seizures in Paediatric,Patients from One Month to Less than Four Years of Age 3UCB Announces Positive Top-Line Phase III Results for Keppra as,Adjunctive Therapy for Partial Onset Seizures in Paediatric,Patients from One Month to Less than Four Years of Age 4UCB Announces Positive Top-Line Phase III Results for Keppra as,Adjunctive Therapy for Partial Onset Seizures in Paediatric,Patients from One Month to Less than Four Years of Age 5Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 2Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 3Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 4Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 5Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 6Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 7